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Abstract
Background: Emerging evidence has shown that vitamin D and magnesium have anti-inflammatory and anti-
depressant effects. Dietary intake of magnesium is associated with reduced body mass index, waist circumference,
body fat percentage, as well as inflammatory biomarkers and depressive symptoms. Vitamin D deficiency has been
linked to inflammation, obesity, and depressive symptoms. This study will test the effects of vitamin D and
magnesium co-supplementation on mood, serum level of brain-derived neurotrophic factor (BDNF), inflammation,
and sirtuin 1 (SIRT1) in obese women.
Methods: We will conduct an 8-week, double-blind, randomized, placebo-controlled clinical trial, in a factorial
design, to evaluate the individual effects of vitamin D and magnesium, and co-supplementation of them, on mood,
serum level of BDNF, inflammation, and SIRT1 in 108 obese women.
Discussion: We hypothesize that vitamin D and magnesium co-supplementation may provide a new adjuvant
therapy through modulation of BDNF, inflammation, and SIRT1 in obese women.
Trial registration: Iranian Registry of Clinical Trials, IRCT20090822002365N23. Registered on 16 August 2019.
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Background
Depression is a global problem with widespread public
health concern [1]. It affects 300 million people globally
with a lifetime prevalence of 17% and has been projected
to be the largest contributor to disease burden by the
year 2030 (https://www.who.int/mental_health/manage-
ment/depression/wfmh_paper_depression_wmhd_2012.
pdf). Depression is linked with high morbidity and mor-
tality, and can have a large negative socioeconomic
impact due to associated functional disabilities and
knock-on healthcare expenditures [2, 3]. Treatment op-
tions consist of antidepressant medications and/or psy-
chotherapy, which are effective in relieving some of the
effects of depression. However, over half of all people on
these medications experience side effects, which can re-
sult in discontinuation of treatment [4]. Therefore, there
is an urgent need for new treatment approaches with
high efficacy and low side-effect profiles.
In a similar manner, obesity is also a global public
health problem. In 2016, approximately 1.9 billion adults
were classified as overweight (body mass index (BMI) >
25 kg/m2), with one-third of these being obese (BMI >
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30 kg/m2) (https://www.who.int/news-room/fact-sheets/
detail/obesity-and-overweight). As with depression,
obesity is associated with decreased quality of life and
reduced life expectancy [5]. This is due to the fact that
obesity is also a major risk factor for non-communicable
diseases such as heart disease, stroke, diabetes, and some
cancers [6]. Recent evidence has emerged that there is a
bidirectional relationship between obesity and depres-
sion as the occurrence of one of these disorders in-
creases the risk of developing the other [7]. Thus,
further studies are needed to increase our understanding
of the underlying mechanisms associated with both con-
ditions, which may lead to improved treatment options.
Obesity has been found to increase the risk of comor-
bid depression by 55%, and depression leads to a 58% in-
creased risk of developing obesity [8]. Also, a number of
epidemiological and meta-studies have demonstrated
that obesity and depression are frequent co-occurring
medical conditions [9–14]. Investigations on the mecha-
nisms linking these two disorders have come to the con-
sensus of dysfunctions in neuroendocrine, inflammation,
and oxidative stress networks [15, 16]. A number of
studies have now shown that depression is marked by
chronic inflammation and that treatment with anti-
cytokine therapies ameliorated the depressive symptoms
[8, 17]. Likewise, the metabolic disruptions in obesity
can result in systemic inflammation and treatments with
anti-inflammatory agents are considered a novel thera-
peutic approach to ameliorate the obesity-related insulin
resistance and other metabolic disturbances [18].
A number of other studies have also demonstrated
that vitamin and mineral deficiency may play a role in
both of these disorders. Magnesium is a vital element in
higher organisms which regulates biochemical processes
in multiple organ systems, including the brain [19]. A
preclinical study showed that mice with low magnesium
levels had increased belligerent behavior, with elevated
levels of noradrenalin compared to control mice with
normal magnesium levels [20]. Clinical studies found an
inverse relationship between circulating magnesium con-
centrations and depressive symptoms [21–24]. Further-
more, one study showed that consumption of 500 mg
magnesium oxide tablets for 8 weeks by depressed pa-
tients with magnesium deficiency led to improvements
in depressive symptoms and magnesium levels [25].
Other studies have found antidepressant-like activities of
magnesium supplementation in bipolar disorder [26], in
women with premenstrual syndrome [27], in individuals
with chronic fatigue syndrome [28], and in elderly indi-
viduals with depression, hypomagnesemia, and type 2
diabetes [29].
Magnesium deficiency can result in changes in cellular
function, leading to the onset of metabolic disorders asso-
ciated with inflammation, particularly in obese individuals
with hypomagnesemia [30–32]. Some studies reported
that dietary intake of magnesium is inversely related to
physiometric measures such as BMI, waist circumference,
and body fat composition [33, 34]. Hypomagnesemia also
leads to decreased antioxidant enzyme activities, with con-
comitant increased production of damaging reactive oxy-
gen species (ROS) by inflammatory cells [35].
Several studies have shown that vitamin D is essential
for normal brain development and function, and vitamin
D deficiency has been linked with neurological disorders,
including depression [36–38]. Vitamin D is also involved
in the initial biosynthetic stages of serotonin, a neuro-
transmitter which has been implicated in both depres-
sion and the mechanism of action of antidepressant
drugs [39]. Vitamin D deficiencies have also been linked
to obesity [38]. For example, studies have found inverse
relationships of vitamin D with total body fat and meta-
bolic syndrome [40]. A study also found decreased hip-
pocampal levels of brain-derived neurotrophic factor
(BDNF) in a preclinical model of depression, and these
were normalized by vitamin D administration [38].
The well-known link of BDNF with depression has led
to its frequent use as a potential biomarker in psychiatric
disorders [41, 42]. However, its link with obesity is not
well understood. In a rodent study, BDNF was found to
regulate appetite via modulation of melanocortin signal-
ing [38]. Furthermore, vitamin D deficiency has been as-
sociated with serum concentrations of inflammatory
biomarkers including interleukin (IL)-6, tumor necrosis
factor (TNF)-α, and C-reactive protein (CRP) in obese
individuals [43], and increased dietary intake of vitamin
D has been linked with lower visceral adiposity and adi-
pocyte size [43].
Other metabolic processes have also been linked with
both obesity and depression. The sirtuins are NAD+-
dependent protein deacetylases in most cells with known
roles in metabolism, the stress response, and aging [44].
Levels of SIRT1 have been found to be low in obesity
and aging, and normalization of SIRT1 levels decreases
disease effects [44]. Studies have also found that SIRT1
promotes insulin signaling through an anti-inflammatory
mechanism and suppresses proinflammatory gene ex-
pression in adipocytes [45]. Also, the reverse association
between SIRT1 and adipose tissue mass and inflamma-
tion was found to be normalized by vitamin D [43].
On the other hand, multiple steps in vitamin D metab-
olism and function require magnesium as a cofactor, in-
cluding vitamin D binding to vitamin D binding protein,
25(OH)D synthesis, 1,25(OH)2D synthesis, 25-
hydroxylase synthesis, and vitamin D receptor expres-
sion. In addition, serum 1,25(OH)2D levels remain low
in individuals with magnesium deficiency even following
vitamin D intake [46]. Magnesium deficiency has also
been found to reduce parathyroid hormone production
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and the number of vitamin D receptors in target cells
[46].
There is not enough information about the individual
effect of vitamin D and magnesium on mood, BDNF,
and SIRT1 and about co-supplementation. The aim of
this study is to evaluate the effects of vitamin D and
magnesium co-supplementation on behavioral measures
of mood, circulating BDNF and inflammation-related
biomarkers, and levels of SIRT1 in obese women.
Methods
Design
We will conduct an 8-week, double-blind, randomized
controlled trial in a factorial design. Participants will
be recruited from staff at the Iran University of Med-
ical Sciences through advertisements. The trial will be
conducted over 8 weeks to evaluate the effects of vita-
min D3 (50,000 IU, one dose weekly) and magnesium
(250 mg magnesium oxide, one dose daily) in obese
women. The output measures will be behavioral read-
outs of mood, circulating levels of BDNF, cytokines,
and SIRT1 (Figs. 1 and 2). The protocol is written in
line with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) checklist
(Additional file 1).
Objectives and hypotheses of the study
The primary objective of the present study is to assess
the effects of vitamin D3 and magnesium co-
supplementation in obese women on readouts of mood,
serum levels of 25(OH)-D, magnesium, BDNF, inflam-
matory biomarkers (hs-CRP, TNF-α, IL-6), and sirtuin 1
levels. For controlling of confounder factors, the study
will evaluate anthropometric indices (weight, body mass
index, and waist circumference), dietary intake of energy
Fig. 1 Protocol flow diagram; we will carry out an 8-week, double-blind, randomized controlled trial to determine the effects of vitamin D and/or
magnesium supplementation on mood, serum level of brain-derived neurotrophic factor (BDNF), inflammation, and sirtuin 1 (SIRT1) in obese
women. BMI body mass index
Abiri and Vafa Trials          (2020) 21:225 Page 3 of 7
and macronutrients, and physical activity levels in the
women at baseline and at the end of the study.
Participants
Participants will be 108 obese women. The inclusion cri-
teria will consist of: BMI = 30–40 kg/m2; age = 18–50
years; serum 25(OH)D < 30 ng/ml; serum magnesium ≤
2 mg/dl; no indication of hormonal changes, auto-
immune disease, diabetes, hypertension, or renal, hep-
atic, parathyroid, hormonal, and gastrointestinal
disorders; not pregnant, breast-feeding, or menopaused;
not taking vitamin D and/or magnesium supplements
and other vitamin–mineral supplements or antidepres-
sant drugs; not taking laxative and/or anti-inflammatory
medications; and not having had a weight loss of ≥ 3 kg
within 2 months leading up to the trial. Exclusion cri-
teria will be less than 90% compliancy with the
treatment.
Ethics and trial registration
The patients who meet the inclusion criteria will be
completely informed about the study protocol. The
protocol of this study was approved by the Medical Eth-
ics Committee of National Institute for Medical Re-
search Development (NIMAD), and is in conformity
with the Declaration of Helsinki (approval number:
IR.NIMAD.REC.1398.181). Each participant will sign the
informed consent form. This clinical trial was registered
on Iranian Registry of Clinical Trials (IRCT registration
number: IRCT20090822002365N23) which is available
online (http://irct.ir/user/trial/20288/view).
Sample size
To estimate the sample size, we considered α = 0.05 and
β = 0.20 in line with previous trials. In addition, we used
1570.5 ng/ml as the standard deviation and 1250.0 ng/ml
as the mean of hs-CRP levels as the primary variable, as
described previously [47]. This resulted in a requirement
of 25 participants in each group. To allow for attrition,
27 participants will be recruited for each group, giving a
total of 108 obese women.
Randomization
Randomization to the different treatment arms will be
performed using computer-generated random numbers.
The 108 participants who meet the criteria will be allo-
cated as such into four treatment groups: 50,000 IU vita-
min D soft gel (weekly), plus a 250-mg magnesium
tablet (daily); 50,000 IU vitamin D soft gel (weekly) plus
a magnesium placebo (daily); vitamin D placebo (weekly)
plus a 250-mg magnesium tablet (daily); and a vitamin D
placebo (weekly) plus a magnesium placebo (daily). The
vitamin D soft gels and magnesium tablets are provided
by Zahravi, Iran and Jalinous, Iran, respectively. The pla-
cebos for vitamin D and magnesium contained oral par-
affin and maltodextrin, respectively, and are supplied by
Zahravi, Iran (these were matched in appearance of the
corresponding soft gels and tablets). Patients will receive
Fig. 2 Timeline of the study; we expect 18months for this trial
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verbal and written counseling on how to consume the
supplements and compliance will be evaluated by tablet
count every 2 weeks.
For blinding, a person who is not involved in the study
protocol will create a randomized list assigning partici-
pants to each treatment arm. The soft gels, tablets, and
corresponding placebos will be placed into unlabeled
identical containers. The study leader will label the con-
tainers with participant numbers using the codes gener-
ated through the randomization. All investigators and
participants will be blinded.
Women who meet the inclusion criteria will be in-
formed completely about the protocol of the study. The
ethics committee will review and approve the final study
protocol. Each participant will sign the informed consent
form.
Outcome measures
Mood will be assessed using the validated Iranian ver-
sion of the Beck Depression Inventory (BDI) [48] at
baseline and after the intervention period. Blood samples
will be collected at both time points after a 12-h over-
night fast. Serum will be prepared according to standard
protocols and stored at –80 °C until analyses. Serum
25(OH)D will be measured by enzyme-linked immune
sorbent assay (ELISA) using the Euro Immun kit (Euro
Immun, Germany). Serum magnesium will be deter-
mined using a spectrophotometric method with an auto-
analyzer (Hitachi 912; Roche Diagnostics). Serum BDNF
will be assessed by ELISA using the ZellBio kit (ZellBio,
Germany). Serum hs-CRP values will be measured using
an immunoturbidimetric method (Pars Azmun, Iran).
Serum TNF-α and IL-6 levels will be assessed by ELISA
using the Bender Med kit (Bender Med, Germany). Sir-
tuin 1 will be evaluated using ELISA with the ZellBio kit
(ZellBio, Germany).
A questionnaire regarding patient medications and
probable supplement use will be recorded at the begin-
ning of the intervention. Dietary intake will be evaluated
by 3 days of 24-h recall questionnaires (2 week days and
1 weekend day) at baseline and at the end of the inter-
vention, and total energy and macronutrient intake will
be estimated using Nutritionist V software. Physical
activity levels will be assessed using the short form of
the International Physical Activity Questionnaire (IPAQ)
at baseline and at the end of the intervention. Physio-
metric measures will be taken after overnight fasting,
with minimal clothing and without shoes, at baseline
and after the intervention. Body weight will be measured
with an accuracy of 0.1 kg using the Beurer scale
(Beurer, Germany). Height will be assessed using a stadi-
ometer to the nearest 0.5 cm in a standing position with-
out shoes. BMI will be computed as body weight
(kilograms) divided by height squared (centimeters
squared). Waist circumference will be evaluated at the
narrowest point above the hips with an unstretched tape
measure.
Statistical analysis
Statistical tests of the outcome measures will be per-
formed using SPSS (version 22.0; SPSS Inc., Chicago, IL,
USA). The normality of distribution will be examined
and confirmed by the Kolmogorov–Smirnov test. All re-
sults will be expressed as mean ± SD. Categorical vari-
ables will be presented as frequencies and percentages.
The chi-square test will be used to test for differences
between categorical variables. Baseline mean differences
will be tested using one-way analysis of variance
(ANOVA). Analysis of covariance (ANCOVA) will be
used to identify differences between the four treatment
arms at the end of study, adjusting for baseline values
and covariates. The comparison of mean values will be
done within groups after the intervention period using
paired-sample t tests. Bonferroni corrections will be used
in pairwise comparisons of the values after the interven-
tion. P < 0.05 will be considered statistically significant.
Discussion
Mounting evidence has demonstrated a two-way rela-
tionship between obesity and depression as a commonly
co-occurring medical situation. Furthermore, both dis-
eases have shown significant links with inflammation.
Moreover, metabolic disruptions in obesity can result in
increased levels of cortisol, leptin, and insulin, leading to
dysregulation of neuroendocrine networks and insulin
resistance. In turn, these conditions can lead to further
inflammatory effects and worsen depression.
Moreover, the literature has demonstrated that vita-
min and mineral deficiency can play a critical role in the
pathogenesis of multiple disorders such as obesity and
depression with clinical repercussions. Magnesium is
one of the most vital elements in the human body and
an obvious relationship between circulating magnesium
concentrations and depressive symptoms has been
shown in some studies. Furthermore, magnesium defi-
ciency is a nutritional problem that results in alterations
in cellular function and biological activity of the resident
molecules, which may lead to the onset of metabolic dis-
orders associated with inflammatory process. This situ-
ation is particularly pronounced in obese individuals
with low serum and dietary levels of magnesium.
Additionally, several studies have reported that vitamin
D deficiency is related to both depressive symptoms and
obesity. Studies of obesity have also demonstrated effects
on major central nervous system biomarkers, such as a
decrease in BDNF levels in the hippocampus with rever-
sal of the effect following vitamin D administration.
SIRT1 is widely located in mammalian cells. Expression
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and enzymatic activity of SIRT1 are low in many non-
communicable diseases, and SIRT1 activation can delay
or ameliorate many of these effects. In addition, SIRT1
protects against diet-induced obesity and inflammation
as well as obesity-related metabolic dysfunction.
Given the known role of vitamin D and magnesium
deficiency in the pathogenesis of many non-
communicable disorders, we will test the effects of their
co-supplementation in obese women on the readouts of
mood and serum levels of BDNF, inflammatory cyto-
kines, and SIRT1.
Trial status
The present research is at the stage of preparing the ma-
terial. Protocol version number 2, dated 18 October
2019. Recruitment began on 20 October 2019, and will
be completed on 20 December 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4122-9.
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
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